Neurona Therapeutics to Present New Preclinical Data and Clinical Trial Plans for Lead Neural Cell Therapy Program, NRTX-1001, at the Annual Meeting of the American Epilepsy Society
December 03, 2021 10:01 ET
|
Neurona Therapeutics
Data from IND-enabling studies show accurate delivery, targeted biodistribution, favorable safety profile, durable suppression of seizures and reduction in disease pathology A first-in-human Phase...
Brain Scientific and LOK Corporation Announce Global Partnership Advancing Innovative Neurodiagnostic Devices
November 22, 2021 08:00 ET
|
Brain Scientific Inc.
NEW YORK, Nov. 22, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- Brain Scientific Inc. (OTCQB: BRSF), a leader in the medical technology market, today announces its partnership with LOK Corporation...
AB Science reçoit l’autorisation de la FDA de reprendre le recrutement des patients dans l'étude confirmatoire de phase 3 du masitinib (AB19001) chez les patients atteints de SLA
November 18, 2021 14:40 ET
|
AB Science
COMMUNIQUE DE PRESSE AB SCIENCE REÇOIT L'AUTORISATION DE LA FOOD AND DRUG ADMINISTRATION (FDA) AMÉRICAINE DE REPRENDRE LE RECRUTEMENT DE PATIENTS DANS L'ÉTUDE DE PHASE 3 DU MASITINIB DANS LA...
AB Science received authorization from the FDA to resume patient enrollment in the confirmatory Phase 3 study of masitinib (AB19001) in patients with ALS
November 18, 2021 14:40 ET
|
AB Science
PRESS RELEASE AB SCIENCE RECEIVES U.S. FOOD AND DRUG ADMINISTRATION (FDA) AUTHORIZATION TO RESUME PATIENT ENROLMENT IN THE PHASE 3 STUDY OF MASITINIB IN AMYOTROPHIC LATERAL SCLEROSIS (ALS) ...
Brain Scientific Announces Third Quarter 2021 Results
November 18, 2021 08:00 ET
|
Brain Scientific Inc.
NEW YORK, Nov. 18, 2021 (GLOBE NEWSWIRE) -- via InvestorWire - Brain Scientific Inc. (OTCQB: BRSF) a leader in the Medical Technology market, reported business highlights and financial results for...
Acumen Pharmaceuticals Reports Financial Results for Third Quarter 2021 and Business Highlights
November 15, 2021 08:00 ET
|
Acumen Pharmaceuticals, Inc.
Acumen’s investigational product candidate, ACU193, is the first humanized monoclonal antibody discovered and developed to selectively target toxic amyloid-beta oligomers (AβOs) to enter clinical...
Athira Pharma Presents Overview and Update from ACT-AD and LIFT-AD Trials of ATH-1017 in mild-to-moderate Alzheimer’s Disease at CTAD Conference
November 10, 2021 11:50 ET
|
Athira Pharma, Inc.
– Balanced baseline characteristics in ACT-AD and LIFT-AD to date –– Topline data from ACT-AD trial targeted for first half of 2022 – BOTHELL, Wash., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Athira...
Brain Scientific Announces the Appointment of Independent Board Members
November 10, 2021 08:00 ET
|
Brain Scientific Inc.
NEW YORK, Nov. 10, 2021 (GLOBE NEWSWIRE) -- InvestorWire -- Brain Scientific Inc. (OTCQB: BRSF), a leader in the Medical Technology market, has announced the appointment of three independent board...
Adhera Therapeutics Announces Appointment of Dr. Zahed Subhan to Board of Directors
November 08, 2021 09:15 ET
|
Adhera Therapeutics, Inc.
Baton Rouge, LA, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCPK: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, is pleased to announce the...
Acumen Pharmaceuticals to Present at Upcoming Investor Conferences
November 08, 2021 08:00 ET
|
Acumen Pharmaceuticals, Inc.
CHARLOTTESVILLE, Va. and CARMEL, Ind., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical stage biopharmaceutical company focused on the development of novel...